NCT04221750CompletedPhase 3
Diet and Exercise Plus Metformin to Treat Frailty in Obese Seniors
Lifestyle Intervention Plus Metformin to Treat Frailty in Older Veterans With Obesity
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
The continuing increase in prevalence of obesity in older adults including many older Veterans has become a major health concern. The clinical trial will test the central hypothesis that a multicomponent intervention consisting of lifestyle therapy (diet-induced weight loss and exercise training) plus metformin will be the most effective strategy for reversing sarcopenic obesity and frailty in older Veterans with obesity.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 114 (actual)
- First submitted
- 2 Jan 2020
- Start date
- 14 May 2021
- Primary completion date
- 31 Jul 2025
- Lead sponsor
- VA Office of Research and Development
- Diseases
- Obesity
- NCT number
- NCT04221750
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 114
- From 14 May 2021 to the primary completion date, 31 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current use of bone acting drugs (e.g. use of estrogen, or androgen containing compound,raloxifene, calcitonin, parathyroid hormone during the past year or bisphosphonates during the last two years)
- Use of any drugs or natural products designed to induce weight loss within past three months
Other illness
- Any major chronic diseases, or any condition that would interfere with exercise or dietary restriction, or use of metformin, in which exercise, dietary restrictions, or metformin are contraindicated, or that would interfere with interpretation of results
- Cardiopulmonary disease (e.g. recent MI, unstable angina, stroke) or unstable disease (e.g., NYHA Class III or IV congestive heart failure, severe pulmonary disease requiring steroid pills or the use of supplemental oxygen) that would contraindicate exercise or dietary restriction
- Severe orthopedic (e.g. awaiting joint replacement) and/or neuromuscular (e.g. multiple sclerosis, active rheumatoid arthritis) disease or impairments that would contraindicate participation in exercise
- Other significant co-morbid disease that would impair ability to participate in the exercise intervention (e.g. severe psychiatric disorder \[e.g. bipolar, schizophrenia\], excess alcohol use \[\>14 drinks per week\])
- Significant cognitive impairment, defined as a known diagnosis of dementia or positive screening test for dementia using the Mini-Mental State Exam (i.e. MMSE score \<24)69
- Uncontrolled hypertension (BP\>160/90 mm Hg)
- History of malignancy during the past 5 years (except non-melanoma skin cancers)
- Osteoporosis (T-score -2.5 and below on hip or spine scan) or history of fragility fractures
- Known history of diabetes mellitus or any of the following:
- Terminal illness with life expectancy less than 12 months, as determined by a physician
- History of excessive alcohol consumption (e.g. 8 or more drinks a week for women and 15 or more drinks a week for men)
Lab values
- Renal impairment as defined by an estimated glomerular filtration rate (eGFR of less than 30 mL/min/1.73 m2) in which metformin is contraindicated
- Fasting blood glucose of 126 mg/dl, or HbA1c of 6.5% or \>
- Taking metformin or any other glucose lowering drug
Other
- Severe visual or hearing impairments that would interfere with following directions
- Positive exercise stress test for ischemia or any indication for early termination of exercise stress testing
- Lives outside of the study site or is planning to move out of the area in the next 2 years
Who the study is looking for
- Age 65 - 85 years
- BMI = or \> 30 kg/m2
- Mild to moderate frailty (score of 18 to 31 in the modified Physical Performance Test)
- Stable body weight (plus/minus 2 kg) during the past 6 months
- Sedentary (regular exercise \<1 h/wk or \<2 x/wk for the last 6 months)
- Willing to provide informed consent
Age in the registry: 65 years to 85 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Michael E. DeBakey VA Medical Center, Houston, TX Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
Related publications
- Metformin added to lifestyle intervention for physical function in older adults with obesity (DEMFOS trial): a randomised controlled trial.Lancet Healthy Longev · 2026 · PMID 42532077
This page is information, not medical advice. Discuss any trial with your doctor.